Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first quarter of this year on generic competition. Net sales fell 5%, or 1% at constant currencies,

Generic competition for Promacta, a blood disorder drug, and Tasigna, a leukemia treatment, is adding pressure on ​Novartis to offset those lost sales with newer drugs or dealmaking, the report said.

The stock is down on a predictable, already-announced Entresto patent cliff (Entresto -42% YoY in Q1) and the market is likely over-discounting near-term noise versus the unchanged full-year outlook (low single-digit core op income decline).

Novartis (NVS) stock dropped 2% as Q1 sales missed estimates at $13.11B. Entresto plunged 42% on generics while CEO warns of U.S. pricing policy risks.

As blockbuster heart failure drug Entresto inches toward a patent cliff, Novartis is calling on the FDA—again—to keep early-bird generics at bay. At the time, Novartis argued greenlighting any generic before 2024 would violate the FDA’s “same ...

Group operating income is down by 12% at US$4.9 billion, below analyst expectations of US$5.1 billion Read more at The Business Times.

Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a mega-blockbuster. Some suggest $10 billion per annum ...

Best practice around value-based contracting, which involves tying reimbursement for drugs (or devices or digital health tools, etc.) to proof that they deliver improved outcomes or lower treatment costs, is an evolving science. Just ask Mark Vineis, VP of ...